Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors

European Journal of Endocrinology

Volumn 164, Issue 1, 2011, Pages 115-122

  Färkkilä, Anniina ^a,b   Anttonen, Mikko ^a,b   Pociuviene, Jurate ^a   Leminen, Arto ^a   Butzow, Ralf ^a,b   Heikinheimo, Markku ^a,b,c   Unkila Kallio, Leila ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Program for Women's Health   (Finland)

^c ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; GRANULOSA CELL TUMOR; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; DISEASE ASSOCIATION; LUTEAL CELL; MICROVASCULARIZATION; PRIMARY TUMOR; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RECURRENT CANCER; RNA ANALYSIS;

ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANULOSA CELL TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 78751553690     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0849     Document Type: Article

References (49)

1. Schumer ST & Cannistra SA. Granulosa cell tumor of the ovary. Journal of Clinical Oncology 2003 21 1180-1189. (doi:10.1200/JCO.2003.10.019)
2. Unkila-Kallio L, Tiitinen A, Wahlstrom T, Lehtovirta P & Leminen A. Reproductive features in women developing ovarian granulosa cell tumour at a fertile age. Human Reproduction 2000 15 589-593. (doi:10.1093/humrep/15.3.589)
3. Pectasides D, Pectasides E & Psyrri A. Granulosa cell tumor of the ovary. Cancer Treatment Reviews 2008 34 1-12. (doi:10.1016/j.ctrv.2007.08.007)
4. Merras-Salmio L, Vettenranta K, Mottonen M & Heikinheimo M. Ovarian granulosa cell tumors in childhood. Pediatric Hematology and Oncology 2002 19 145-156. (doi:10.1080/088800102753541297)
5. Fujimoto T, Sakuragi N, Okuyama K, Fujino T, Yamashita K, Yamashiro S, Shimizu M & Fujimoto S. Histopathological prognostic factors of adult granulosa cell tumors of the ovary. Acta Obstetricia et Gynecologica Scandinavica 2001 80 1069-1074.
6. Cronje HS, Niemand I, Bam RH & Woodruff JD. Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry. American Journal of Obstetrics and Gynecology 1999 180 323-327. (doi:10.1016/S0002- 9378(99)70207-3)
7. Ferrara N, Gerber HP & LeCouter J. The biology of VEGF and its receptors. Nature Medicine 2003 9 669-676. (doi:10.1038/nm0603-669)
8. Lam PM & Haines C. Vascular endothelial growth factor plays more than an angiogenic role in the female reproductive system. Fertility and Sterility 2005 84 1775-1778. (doi:10.1016/j.fertnstert.2005.05.059) (Pubitemid 41785689)
9. Geva E & Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertility and Sterility 2000 74 429-438. (doi:10.1016/S0015-0282(00)00670-1)
10. Kamat BR, Brown LF, Manseau EJ, Senger DR & Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. American Journal of Pathology 1995 146 157-165.
11. Otani N, Minami S, Yamoto M, Shikone T, Otani H, Nishiyama R, Otani T & Nakano R. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. Journal of Clinical Endocrinology and Metabolism 1999 84 3845-3851. (doi:10.1210/jc.84.10. 3845)
12. Sugino N, Kashida S, Takiguchi S, Karube A & Kato H. Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy. Journal of Clinical Endocrinology and Metabolism 2000 85 3919-3924. (doi:10.1210/jc.85.10.3919)
13. Olson TA, Mohanraj D, Carson LF & Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Research 1994 54 276-280.
14. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004 9 (Supplement 1) 2-10. (doi:10.1634/theoncologist.9- suppl-1-2)
15. Heath VL & Bicknell R. Anticancer strategies involving the vasculature. Nature Reviews. Clinical Oncology 2009 6 395-404. (doi:10.1038/nrclinonc.2009.52)
16. Han ES & Monk BJ. Bevacizumab in the treatment of ovarian cancer. Expert Review of Anticancer Therapy 2007 7 1339-1345. (doi:10.1586/14737140.7. 10.1339)
17. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD & Penson RT. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. Journal of Clinical Oncology 2009 27 5601-5606. (doi:10.1200/JCO.2009.23.2777)
18. Natale RB, Bodkin D, Govindan R, Sleckman BG, Rizvi NA, Capo A, Germonpre P, Eberhardt WE, Stockman PK, Kennedy SJ & Ranson M. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. Journal of Clinical Oncology 2009 27 2523-2529. (doi:10.1200/JCO.2008.18.6015)
19. Schmidt M, Kammerer U, Segerer S, Cramer A, Kohrenhagen N, Dietl J & Voelker HU. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2008 139 72-78. (doi:10.1016/j.ejogrb.2008.02.009)
20. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM & Brown J. Antiangiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecologic Oncology 2009 114 431-436. (doi:10.1016/j.ygyno.2009.04.021)
21. Kesterson JP, Mhawech-Fauceglia P & Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecologic Oncology 2008 111 527-529. (doi:10.1016/j.ygyno. 2008.07.015)
22. Anttonen M, Unkila-Kallio L, Leminen A, Butzow R & Heikinheimo M. High GATA-4 expression associates with aggressive behavior, whereas low anti-Mullerian hormone expression associates with growth potential of ovarian granulosa cell tumors. Journal of Clinical Endocrinology and Metabolism 2005 90 6529-6535. (doi:10.1210/jc.2005-0921)
23. Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M & Huntsman DG. Mutation of FOXL2 in granulosa-cell tumors of the ovary. New England Journal of Medicine 2009 360 2719-2729. (doi:10.1056/NEJMoa0902542)
24. Jamieson S, Butzow R, Andersson N, Alexiadis M, Unkila-Kallio L, Heikinheimo M, Fuller PJ & Anttonen M. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Modern Pathology 2010 23 1477-1485. (doi:10.1038/modpathol.2010.145)
25. Kim MS, Hur SY, Yoo NJ & Lee SH. Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. Journal of Pathology 2010 221 147-152. (doi:10.1002/path.2688)
26. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G & Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine 1998 4 844-847. (doi:10.1038/nm0798-844)
27. Nishi Y, Yanase T, Mu Y, Oba K, Ichino I, Saito M, Nomura M, Mukasa C, Okabe T, Goto K, Takayanagi R, Kashimura Y, Haji M & Nawata H. Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology 2001 142 437-445. (doi:10.1210/en.142.1.437)
28. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ & von Pawel J. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. Journal of Clinical Oncology 2009 27 3836-3841. (doi:10.1200/JCO.2008.20.8355)
29. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jurgensmeier JM, Puchalski TA, Young H, Saunders O & Unger C. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 2007 25 3045-3054. (doi:10.1200/JCO.2006.07.2066)
30. Tammela T, Enholm B, Alitalo K & Paavonen K. The biology of vascular endothelial growth factors. Cardiovascular Research 2005 65 550-563. (doi:10.1016/j.cardiores.2004.12.002) (Pubitemid 40138976)
31. Wang D, Donner DB &Warren RS. Homeostatic modulation of cell surface KDR and Flt1 expression and expression of the vascular endothelial cell growth factor (VEGF) receptor mRNAs by VEGF. Journal of Biological Chemistry 2000 275 15905-15911. (doi:10.1074/jbc.M001847200)
32. Masood R, Cai J, Zheng T, Smith DL, Hinton DR & Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001 98 1904-1913. (doi:10.1182/blood.V98. 6.1904)
33. Sher I, Adham SA, Petrik J & Coomber BL. Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. International Journal of Cancer 2009 124 553-561. (doi:10.1002/ijc.23963)
34. Weigand M, Hantel P, Kreienberg R & Waltenberger J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 2005 8 197-204. (doi:10.1007/s10456-005-9010-0)
35. Sims TL, Williams RF, Ng CY, Rosati SF, Spence Y & Davidoff AM. Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery 2008 144 269-275. (doi:10.1016/j.surg.2008.04.009)
36. Park JE, Chen HH, Winer J, Houck KA & Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. Journal of Biological Chemistry 1994 269 25646-25654.
37. Secord AA, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA & Berchuck A. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 2007 106 221-232. (doi:10.1016/j.ygyno.2007.03.021)
38. Carrillo de Santa Pau E, Arias FC, Caso Pelaez E, Munoz Molina GM, Sanchez Hernandez I, Muguruza Trueba I, Moreno Balsalobre R, Sacristan Lopez S, Gomez Pinillos A & del Val Toledo Lobo M. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 2009 115 1701-1712. (doi:10.1002/cncr.24193)
39. Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG & Rollason TP. Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary. International Journal of Gynecological Pathology 2007 26 395-403. (doi:10.1097/pgp.0b013e318063bed7)
40. Juric G, Zarkovic N, Nola M, Tillian M & Jukic S. The value of cell proliferation and angiogenesis in the prognostic assessment of ovarian granulosa cell tumors. Tumori 2001 87 47-53. (Pubitemid 32273852)
41. Miller BE, Barron BA, Wan JY, Delmore JE, Silva EG & Gershenson DM. Prognostic factors in adult granulosa cell tumor of the ovary. Cancer 1997 79 1951-1955. (doi:10.1002/(SICI)1097-0142(19970515)79:10〈1951::AID- CNCR16〉3.0.CO;2-U)
42. Fox H. Pathologic prognostic factors in early stage adult-type granulosa cell tumors of the ovary. International Journal of Gynecological Cancer 2003 13 1-4. (doi:10.1046/j.1525-1438.2003.13050.x)
43. Malmstrom H, Hogberg T, Risberg B & Simonsen E. Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecologic Oncology 1994 52 50-55. (doi:10.1006/gyno.1994.1010)
44. Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempfer CB & Reinthaller A. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecologic Oncology 2006 103 512-517. (doi:10.1016/j.ygyno.2006.03.058)
45. Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ & Sood AK. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clinical Cancer Research 2002 8 3193-3197.
46. Barton DP, Cai A, Wendt K, Young M, Gamero A & De Cesare S. Angiogenic protein expression in advanced epithelial ovarian cancer. Clinical Cancer Research 1997 3 1579-1586.
47. Homesley HD, Bundy BN, Hurteau JA & Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecologic Oncology 1999 72 131-137. (doi:10.1006/gyno.1998.5304)
48. Nagy JA, Masse EM, Herzberg KT, Meyers MS, Yeo KT, Yeo TK, Sioussat TM & Dvorak HF. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Research 1995 55 360-368.
49. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marme D & Gastl G. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999 85 178-187. (doi:10.1002/(SICI)1097-0142(19990101)85:1〈178::AID-CNCR25〉3. 0.CO;2-7) (Pubitemid 29031373)